title: CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.
abstract: Cytochrome P450 2A6 (CYP2A6) is an enzyme involved in the metabolism of some tobacco carcinogens, which is an important risk factor of lung cancer. Among CYP2A6 allelic variants, CYP2A6*4 presents a whole gene deletion that accounts for the majority of poor metabolizer. In this study, a meta-analysis was performed to assess the association between CYP2A6*4 and risk of lung cancer. Literature searches were conducted to identify peer-reviewed manuscripts published up to December 20, 2012. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were calculated in a fixed-effects model and a random-effects model when appropriate. Eight eligible studies with 3,203 lung cancer cases and 2,839 controls were included in this study. Overall, no significant association was observed in CYP2A6*4 with the risk of lung cancer under any genetic model for all samples after correction. However, subgroup analysis showed that significant associations were observed in Asian with pooled OR (95 %CI) of 0.761 (0.672-0.861) for allele comparison, 0.769 (0.668-0.886) for dominant model, and 0.522 (0.359-0.760) for recessive model. Furthermore, after stratifying Asian samples according to smoking status, significant associations were only observed in smokers with pooled OR (95 %CI) of 0.713 (0.607-0.838) for allele comparison, 0.720 (0.596-0.869) for dominant model, and 0.444 (0.275-0.715) for recessive model. This meta-analysis suggests that the CYP2A6*4 polymorphism was associated with susceptibility of lung cancer for smokers in Asian. The whole gene deletion of CYP2A6 might decrease the risk of tobacco-related lung cancer in Asian.
authors: Department of Respiratory Medicine, The first affiliated Hospital of Chongqing Medical University, 400016, Chongqing, China.
authors: Yu-liang
authors: YL
authors: Liu
authors: Yu
authors: Y
authors: Xu
authors: Fan
authors: F
authors: Li
authors: Hong
authors: H
authors: Chen
authors: Shu-liang
authors: SL
authors: Guo
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D044466:Asian People; D016022:Case-Control Studies; D065637:Cytochrome P-450 CYP2A6; D060467:Disease Resistance; D017353:Gene Deletion; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D011110:Polymorphism, Genetic; D012907:Smoking / Q000009:adverse effects* / Q000235:genetics
chemical_list: D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: Biochem Biophys Res Commun. 2005 Dec 9;338(1):306-10
references: 16176798
references: Cancer Res. 2003 Nov 15;63(22):8057-61
references: 14633739
references: Carcinogenesis. 2000 Jun;21(6):1227-32
references: 10837014
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Clin Chim Acta. 2013 Feb 1;416:11-9
references: 23178447
references: Br Med Bull. 1996 Jan;52(1):22-34
references: 8746294
references: Annu Rev Pharmacol Toxicol. 2003;43:149-73
references: 12171978
references: Environ Mol Mutagen. 2013 Mar;54(2):133-40
references: 23203414
references: Lung Cancer. 1995 Jun;12(3):167-81
references: 7655828
references: Cancer Res. 2003 Nov 15;63(22):7581-3
references: 14633670
references: Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):297-9
references: 21108885
references: Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
references: 11602373
references: Biochem Pharmacol. 1999 Jun 15;57(12):1407-13
references: 10353262
references: Pharmacogenetics. 2001 Feb;11(1):39-44
references: 11207029
references: FEBS Lett. 1999 Oct 29;460(2):321-7
references: 10544257
references: Biochem Biophys Res Commun. 2002 Jan 11;290(1):318-24
references: 11779172
references: Pharmacogenetics. 2004 Sep;14(9):615-26
references: 15475735
references: Drug Metab Pharmacokinet. 2006 Dec;21(6):475-84
references: 17220563
references: Clin Pharmacol Ther. 2001 Jan;69(1):72-8
references: 11180041
references: Pharmacogenomics J. 2005;5(1):42-8
references: 15534625
references: J Natl Cancer Inst. 2011 Sep 7;103(17):1342-6
references: 21747048
references: Pharmacogenetics. 2004 Oct;14(10):701-5
references: 15454735
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Pharmacogenomics J. 2005;5(4):271-5
references: 15940289
references: Arch Toxicol. 1999 Mar;73(2):65-70
references: 10350185
references: Br J Clin Pharmacol. 2002 Nov;54(5):511-7
references: 12445030
references: Pharmacogenetics. 2001 Nov;11(8):687-98
references: 11692077
references: Carcinogenesis. 2004 Dec;25(12):2451-8
references: 15308589
references: Biochem Biophys Res Commun. 1999 Aug 11;261(3):658-60
references: 10441482
references: Drug Metab Dispos. 1996 Nov;24(11):1212-7
references: 8937855
references: Drug Metab Pharmacokinet. 2011;26(5):516-22
references: 21791872